Abstract
The somatic activation of PI3K/AKT pathway mutations, PIK3CA and AKT1, and ESR1 mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive procedure to quickly assess and monitor disease progression or therapeutic effect in breast cancer (BC) patients, but the clinical significance of these mutations in late treatment lines (TLs) remains unclear. The subjects of this study were a total of 251 plasma samples from 128 estrogen receptor-positive (ER+) BC patients. Of these plasma samples, 133 were from 73 primary BC (PBC) patients, and 118 plasma samples were from 68 metastatic BC (MBC) patients. We developed droplet digital PCR (ddPCR) assays to verify the clinical significance of PIK3CA, AKT1, and ESR1 mutations in these patients. cfDNA PIK3CA mutations were observed in 15.1% of the PBC patients, while a cfDNA AKT1 mutation was observed in 1.4% of patients, and cfDNA ESR1 mutations were observed in 2.7% of patients. Patients with detectable cfDNA PIK3CA mutations were not associated with clinical outcomes. According to the TL, the prevalence of the PIK3CA and ESR1 mutations in cfDNA were lower in early TLs compared with late TLs. In the early TL group, patients with cfDNA PIK3CA mutations had a shorter time to ...Continue Reading
References
May 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Sherene LoiChristos Sotiriou
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel N HortobagyiJosé Baselga
Feb 28, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ebubekir DiricanAyşe Özer
Mar 8, 2016·The Lancet Oncology·Massimo CristofanilliDennis Slamon
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charlotte FribbensNicholas C Turner
Aug 16, 2016·BMC Cancer·Marion RudolphJoachim Reischl
Aug 18, 2016·JAMA Oncology·Sarat ChandarlapatyMary Ellen Moynahan
Nov 26, 2016·Cancer Treatment Reviews·Lindsay AngusStefan Sleijfer
Feb 10, 2017·British Journal of Cancer·Mary Ellen MoynahanSarat Chandarlapaty
Sep 9, 2017·Oncotarget·Takashi TakeshitaHirotaka Iwase
Citations
Nov 28, 2018·International Journal of Cancer. Journal International Du Cancer·Kamal PandeyYong Wha Moon
Jun 13, 2019·Expert Review of Molecular Diagnostics·Marcela CarausuLuc Cabel
Mar 27, 2020·Medical Sciences : Open Access Journal·Ugo TestaElvira Pelosi
Nov 16, 2019·Scientific Reports·Takashi TakeshitaKazuaki Takabe
May 7, 2019·Aging·Weiyang LouWeimin Fan
Jun 30, 2019·Cellular and Molecular Life Sciences : CMLS·Corinna KeupSabine Kasimir-Bauer
May 1, 2020·Cancers·Corinna KeupSabine Kasimir-Bauer
Dec 5, 2019·Cancers·Irene De SantoLuca Malorni
Jul 9, 2020·International Journal of Breast Cancer·Elizabeth J AndersonLisa E Davis
Jan 2, 2021·Frontiers in Oncology·Hao LiaoHuiping Li
Jan 8, 2021·Molecular Biology Reports·Georgia GomatouElias Kotteas
Dec 29, 2020·Frontiers in Pharmacology·Zhen LiCeshi Chen
Jan 6, 2021·Cancers·Takashi TakeshitaKazuaki Takabe
Jan 6, 2021·International Journal of Molecular Sciences·Natasha M van PoppelenEmine Kiliҫ
Feb 14, 2021·Cancers·Maria PanagopoulouEkaterini Chatzaki
Mar 26, 2021·Scientific Reports·Axel MuendleinThomas Decker
May 1, 2021·Cancers·Lucrezia RaimondiGian Paolo Spinelli
Jun 3, 2021·Cancers·Masanori OshiKazuaki Takabe
Sep 21, 2019·Analytical Chemistry·Athina MarkouEvi Lianidou
Jan 16, 2022·Clinical and Experimental Medicine·Elaheh TarighatiHojjat Mahani